Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerezyme for Skeletal Disease in Type I Gaucher Disease
NCT00365131Phase 4Completed
- Sponsor
- Sanofi
- Start
- Dec 1997
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imiglucerase in Gaucher disease type I (GD1), sponsored by Sanofi. Primary endpoints: Skeletal response over 4 years of Cerezyme therapy, Bone pain at 48 months and 4 more. Started Dec 1997; status: completed.
02
Drugs
imiglucerase
03
Conditions
Gaucher disease type I (GD1)
Beyond the preview
Go deeper on NCT00365131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365131.